ClinicalTrials.gg
RecruitingNCT06627504T1DREaMUpdated Jun 3, 2026

Type 1 Diabetes REst for Metabolic Health

An interventional study of Sleep Health and Circadian Timing Intervention in Type 1 Diabetes (T1D) and Sleep Health, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 14 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
14 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver — 10 open to participants now, 13 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · University of Colorado, Denver.

Planned enrollment
18th of 44
50 · median 44
Started
2025
the only one that year
No phase
25 of 58
6 open now
Primary completion
2029-05
later than 11 of 12 live
Registered
55th of 58
by date

Among the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, this one is the 18th largest by planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2025, is one of 25 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 55th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

10 of the 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 14 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Diabetes Mellitus, Type 1 by University of Colorado, Denver, or all of them as a file.
02

Study summary

Research has shown a link between poor sleep health and late circadian timing with cardiometabolic health in adolescents with type 1 diabetes (T1D). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in T1D, which begins as early as adolescence, and current therapies are limited. Therefore, this study plans to investigate whether cardiometabolic health can be improved with increased sleep duration and advanced circadian timing in adolescents with T1D with habitually insufficient sleep. To answer this question, investigators will study adolescents with T1D who get \<7h sleep on school nights and measure changes in insulin sensitivity, glycemic control, and vascular function after one month of a sleep and circadian intervention (1+ hour longer time in bed each night plus evening melatonin and morning light therapy) compared to one month of typical sleep (usual school schedule).

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Sleep Health
04

Who can participate

Ages eligible
14 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High school students between the ages of 14-19 years;
  • Diagnosed with T1D for ≥1 year;
  • Using an insulin pump or other automated insulin delivery system;
  • Have typically insufficient sleep, defined by ≤ 7 h per night on school days (assessed by actigraphy);
  • With or at risk for obesity based on either above-average weight ( ≥50th percentile) or parental history of obesity (BMI ≥ 30 kg/m2);
  • Tanner stage 4 or 5, based on breast development for girls and testicular size for boys.

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of a sleep disorder (e.g., insomnia, obstructive sleep apnea) or an elevated screening score on the OSA subscale of the Sleep Disorders Inventory for Students-Adolescents measure
  • Regular use of medications affecting sleep (e.g., stimulants, atypical antipsychotics, melatonin or other sleep aids);
  • Regular use of medications affecting IR (systemic , adjunctive diabetes medications);
  • ≥12%;
  • Severe illness or DKA within 60 days;
  • IQ\<70 or severe mental illness impacting sleep or ability to participate in the study;
  • Night-shift employment or other obligations that would preclude adherence to the intervention.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sleep Health and Circadian Timing Intervention

    Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.

    Behavioral: Sleep Health and Circadian Timing Intervention

  • No intervention
    Typical Sleep

    Participants will be asked to sleep on their usual schedule.

Interventions

  • BehavioralSleep Health and Circadian Timing Intervention

    Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.

06

What researchers measure

Primary outcomes

  1. Insulin Sensitivity

    Steady-state glucose infusion rate (M) normalized to free fat mass (FFM) and to steady-state insulin (M/I, \[mg/kg FFM/min\]/insulin) measured with hyperinsulinemic euglycemic clamp

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

  2. Cardiovascular Function

    Value of central aortic stiffness from cardiovascular MRI

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

  3. Glycemic Control

    Value of mean sensor glucose assessed with continuous glucose monitor

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

Secondary outcomes

  1. Inflammation

    Laboratory values of hs-CRP, IL-6, and TNF-alpha

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

  2. Adipokines

    Laboratory values of leptin and adiponectin

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

  3. Cortisol

    Laboratory values of cortisol

    Time frame: Baseline (following 1 month typical sleep) and following 1 month intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All fully deidentified raw and processed/scored data will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Access to the data will be made at the end of the grant award or when a publication has been submitted. Once the data are submitted, the archive will control the long-term persistence of the data set.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2029, 45 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 45 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 4, 2024
StartActual
Aug 12, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06627504
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Aug 12, 2025
Primary completion
May 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Angel Bernard, BS
Contact
angel.bernard@childrenscolorado.org
720-777-3491
Stacey L Simon, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion